METHODS FOR TREATING PULMONARY HYPERTENSION

• US 20180125851A1
• Filed: 07/07/2017
• Published: 05/10/2018
• Est. Priority Date: 01/12/2015
• Status: Active Grant

• Current Assignee: Reviva Pharmaceuticals, Inc.
• Original Assignee: Reviva Pharmaceuticals, Inc.
• Inventors: Bhat, Laxminarayan, Cantillon, Marc, Wallis, Ellen M., Bhat, Seema Rani
• Granted Patent: US 10,441,590 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Claims

1. A method of treating pulmonary hypertension in a subject, the method comprising administering to a subject suffering from pulmonary hypertension an effective amount of a compound of Formula I,

2. The method according to claim 1, wherein A is —

O—

(CH₂)_n—

.

3. The method according to claim 1, wherein A is —

(CH₂)_n—

.

4. The method according to claim 1, wherein A is —

NH—

C(O)—

(CH₂)_n—

, —

CH₂—

NH—

C(O)—

(CH₂)_n—

, —

CH₂—

C(O)—

NH—

(CH₂)_n—

, or —

(CH₂)_n—

C(O)—

NH—

CH₂—

CH₂—

.

5. The method according to claim 1, wherein R³, R⁴, R⁶, R⁷, and R⁸ are hydrogen.

6. The method according to any one of claim 5, wherein R¹ and R² are independently H, halogen, or alkoxy.

7. The method according to claim 6, wherein R¹ is H, and R² is methoxy.

8. The method according to claim 6, wherein R¹ and R² are chloro.

9. The method according to claim 1, wherein A is —

O—

(CH₂)_n—

; and

R³, R⁴, R⁶, R⁷, and R⁸ are independently hydrogen or alkyl.

10. The method according to claim 1, wherein the compound is in the form of a hydrochloride salt.

11. The method according to claim 1, wherein the compound is

12. The method according to claim 1, wherein the compound is

13. The method according to claim 1, wherein the compound is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent.

14. The method according to claim 1, wherein the compound is orally administered.

15. The method according to claim 1, which treats pulmonary arterial hypertension.

16. The method according to claim 1, which treats pulmonary hypertension in a subject with chronic obstructive pulmonary disease (COPD).

17. The method according to claim 1, which treats pulmonary hypertension in a subject with sickle cell disease.

18. The method according to claim 1, which treats pulmonary hypertension in a subject with human immunodeficiency virus (HIV).

19. The method according to claim 1, which further treats depression in the subject.

20. The method according to claim 1, which further treats anxiety in the subject.